ClinicalTrials.gg

Astrocytoma clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 689 studies for Astrocytoma across more than 10 countries. 81 are recruiting or about to start. 84 of them are mainly about Astrocytoma (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17. Counting its narrower condition Glioblastoma too: 2,370 studies, 487 open.

ClinicalTrials.gov finds 2,325 studies for Astrocytoma. How that becomes 687 here

This page counts the studies the registry files under Astrocytoma, and those it files under no condition that list Astrocytomathemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 8, 2026. How condition pages count

  1. 2,325Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −1,618Filed under a narrower condition, counted on its own pageGlioblastoma 1,618
  3. −6List Astrocytoma as a condition, but the registry did not file them under itMost often written as “Adult Noninfiltrating Astrocytoma” (1), “Adult Infiltrating Astrocytoma” (1), and “Childhood Cerebral Anaplastic Astrocytoma” (1). The registry filed them under other conditions only, most often Oligodendroglioma (4) and Glioma (4).
  4. −14Match it another way9 name it in the title and 5 in a keyword.
  5. 687The count on this page8 of them list Astrocytoma in their own words; the registry filed them under no condition.

Status

Completed
404
Terminated
99
Recruiting
68
Status unknown
43
Active, not recruiting
30
Withdrawn
27

Phase

Phase 1
316
Phase 2
262
Phase 3
53
Early Phase 1
14
Phase 4
2

Where

United States
553
Canada
69
Australia
41
Germany
39
Netherlands
36
Switzerland
31

Who develops what

Add Astrocytoma to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 6 programs from 5 companies, 3 with this as their studies’ main aim; 2 with a live phase 3 study; 0 primary completions in the next 12 months. Compare HUTCHMED and Nuvation Bio here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
TemozolomideRecent, limited
Evidence
  • NCT05417594 · AstraZeneca · Phase 2 · live · background · “Temozolomide (TMZ)” · registered May 2022
  • NCT03150862 · BeOne Medicines · Phase 2 · background · “TMZ” · registered May 2017
  • NCT02655601 · BioMimetix JV, LLC · Phase 2 · background · “Temozolomide” · registered Jan 2016
  • NCT02414165 · Tocagen Inc. · Phase 3 · comparator · “Temozolomide” · registered Apr 2015
  • NCT00761280 · Isarna Therapeutics GmbH · Phase 3 · comparator · “temozolomide” · registered Sep 2008
Merck & Co., Inc23% of its industry studiesUS: off-patent, 7 generics marketedEU: off-patent, 4 generics authorized11 study
BevacizumabRecent, limited
Evidence
  • NCT06047379 · Neonc Technologies, Inc. · Phase 2 · live · background · “Bevacizumab” · registered Aug 2023
  • NCT03149003 · Sumitomo Pharma Co., Ltd. · Phase 3 · background · “Bevacizumab” · registered May 2017
  • NCT02414165 · Tocagen Inc. · Phase 3 · comparator · “Bevacizumab” · registered Apr 2015
Hoffmann-La Roche48% of its industry studiesUS: Hoffmann-La Roche (FDA 2004) + 6 othersEU: Hoffmann-La Roche (EMA 2005) + 7 others11 study
CarboplatinRecent, limitedPhase 4 trial recorded
Evidence
  • NCT06047379 · Neonc Technologies, Inc. · Phase 2 · live · background · “Carboplatin” · registered Aug 2023
  • NCT02684058 · Novartis · Phase 2 · comparator · “Carboplatin” · registered Feb 2016
Eli Lilly and Company16% of its industry studies11 study

9 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
safusidenib☆ Track2 live phase-3 studies: NCT05303519, NCT07712757Nuvation Bio Inc.
ranosidenib☆ Track1 live phase-3 study: NCT07912398HUTCHMED

The 2 in phase 3 with the nearest primary completion, of 6 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (0)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

None in the next 12 months.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Astrocytoma studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Alkylating agents 5 open · Tyrosine kinase inhibitors (TKIs) 2 open · Immune checkpoint inhibitors 2 open · Angiogenesis inhibitors 1 open · mTOR inhibitors 1 open

Coming up

38studies finish main data collection within a year2 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 68 Astrocytoma studies recruiting now, 40 (59%) set no upper age limit and 14 (21%) stop at 75 or younger. 15 (22%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 3 (4%) take healthy volunteers.

Recruiting studies that take each age, of 68
AgeWomenMen
1011 (16%)11 (16%)
1865 (96%)65 (96%)
3061 (90%)61 (90%)
4058 (85%)58 (85%)
5058 (85%)58 (85%)
6557 (84%)57 (84%)
7556 (82%)56 (82%)
8551 (75%)51 (75%)

Across all 689 studies, recruiting or not: 31% stop at 75 or younger and 26% at 65; 32% take children; <1% are for women only and <1% for men only; 1% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Astrocytoma studies take

Of 82 phase 1 interventional studies under Astrocytoma, half reached primary completion within 50 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 150 mo35–78 · 82 studies—49 mo35–78 · 72 studies
Phase 1/273 mo53–185 · 25 studies——
Phase 252 mo39–100 · 51 studies—54 mo41–100 · 45 studies
Observational94 mo54–104 · 26 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 689. Browse all 689 → or search them.